Business Segment Information (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Apr. 30, 2013		Apr. 30, 2012
Net revenue	$ 8,323		$ 7,149
Sales and marketing costs	(2,665)		(2,928)
Stock compensation expense	(2,376)		(3,323)
Personalized Oncology Solutions [Member]
Net revenue	2,390		2,332
Direct cost of services	(2,604)		(2,331)
Sales and marketing costs	(1,496)		(1,752)
Other operating expenses	(134)		0
Stock compensation expense	0	[1]	0	[1]
Segment profit (loss)	(1,844)		(1,751)
Translational Oncology Solutions [Member]
Net revenue	5,933		4,817
Direct cost of services	(2,637)		(2,533)
Sales and marketing costs	(938)		(936)
Other operating expenses	(1,753)		(2,898)
Stock compensation expense	0	[1]	0	[1]
Segment profit (loss)	605		(1,550)
Unallocated Corporate Overhead [Member]
Net revenue	0		0
Direct cost of services	0		0
Sales and marketing costs	0		0
Other operating expenses	(2,606)		(2,441)
Stock compensation expense	(2,376)	[1]	(3,323)	[1]
Segment profit (loss)	(4,982)		(5,764)
Consolidated [Member]
Net revenue	8,323		7,149
Direct cost of services	(5,241)		(4,864)
Sales and marketing costs	(2,434)		(2,688)
Other operating expenses	(4,493)		(5,339)
Stock compensation expense	(2,376)	[1]	(3,323)	[1]
Segment profit (loss)	$ (6,221)		$ (9,065)

[1] Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.